Andere talen IRLAB Therapeutics AB

Aandelen

IRLAB A

SE0012675361

Beurs gesloten - Nasdaq Stockholm Andere beurzen 17:29:33 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
10,25 ^SEK	-8,48%		-22,35%	+36,67%

22/03	IRLAB Therapeutics ontvangt notulen van einde fase 2-bijeenkomst die de afstemming met de FDA over het fase III-programma voor mesdopetam bevestigen	CI
19/03	IRLAB Therapeutics AB (publ) Mesdopetam vertoont antipsychotische eigenschappen in een geavanceerd model van de ziekte van Parkinson-psychose	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

IRLAB to present at Redeye Investor Forum	16/04
IRLAB receives minutes from End-of-Phase 2 meeting confirming alignment with the FDA on the Phase III program for mesdopetam	25/03
IRLAB Therapeutics Receives Minutes from End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program for Mesdopetam	22/03
IRLAB receives minutes from End-of-Phase 2 meeting confirming alignment with the FDA on the Phase III program for mesdopetam	22/03
IRLAB Therapeutics AB Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson's Disease Psychosis	19/03
IRLAB Therapeutics : mesdopetam displays antipsychotic properties in an advanced model of Parkinson's disease psychosis	19/03
IRLAB’s mesdopetam displays antipsychotic properties in an advanced model of Parkinson’s disease psychosis	19/03
IRLAB to present at Life Science-dagen in Gothenburg and have a fireside chat with ABG	29/02
IRLAB to present at the Bayes@Lund 2024 Conference in Lund, Sweden on March 7	28/02
IRLAB to present clinical and preclinical data at the AD/PD™ 2024: 18th International Conference on Alzheimer’s & Parkinson’s Diseases	27/02
IRLAB has completed a successful End-of-Phase 2 meeting with the FDA on the design of the Phase III program for mesdopetam	22/02
IRLAB Therapeutics AB Completes End-Of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam	22/02
IRLAB's pioneering Phase IIb study with pirepemat, React-PD, provides new insights in specific Parkinson's patient population and enables a data driven prediction of study timelines	07/02
IRLAB publishes year-end report for the period January-December 2023	07/02
IRLAB Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	07/02
IRLAB’s pioneering Phase IIb study with pirepemat – React-PD – provides new insights in specific Parkinson’s patient population and enables a data driven prediction of study timelines	06/02
IRLAB's Pioneering Phase IIb Study Withpirepemat - React-PD - Provides New Insights in Specific Parkinson's Patient Population and Enables a Data Driven Prediction of Study Timelines	06/02
IRLAB, Invitation to the Year-end Report 2023 presentation and webcast	01/02
IRLAB: Invitation to the Year-end Report 2023 presentation and webcast	31/01
IRLAB Therapeutics AB(OM:IRLAB A) added to OMX Nordic Small Cap Index	04/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen IRLAB Therapeutics AB

Aandelen

IRLAB A

SE0012675361

Andere talen

Filters